165 related articles for article (PubMed ID: 35733338)
1. CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma.
Ma Y; Kang B; Li S; Xie G; Bi J; Li F; An G; Liu B; Li J; Shen Y; Xu X; Yang H; Yang Y; Gu Y; Wu N
Mol Ther; 2022 Nov; 30(11):3341-3357. PubMed ID: 35733338
[TBL] [Abstract][Full Text] [Related]
2. Genomic sequencing and editing revealed the GRM8 signaling pathway as potential therapeutic targets of squamous cell lung cancer.
Zhang P; Kang B; Xie G; Li S; Gu Y; Shen Y; Zhao X; Ma Y; Li F; Si J; Wang J; Chen J; Yang H; Xu X; Yang Y
Cancer Lett; 2019 Feb; 442():53-67. PubMed ID: 30391781
[TBL] [Abstract][Full Text] [Related]
3. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
4.
Grandits AM; Bromberger S; Heller G; Reinoehl BA; Tomasich E; Schossleitner K; Berghoff AS; Fuereder T; Wieser R
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162973
[TBL] [Abstract][Full Text] [Related]
5. PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas.
Bao Z; Ji W; Yang Y; Chen Z; Li Z; Wang K; Lu T; Yu Y; Xia W; Lu S
Exp Cell Res; 2020 Oct; 395(2):112187. PubMed ID: 32721391
[TBL] [Abstract][Full Text] [Related]
6. PAX8 and MECOM are interaction partners driving ovarian cancer.
Bleu M; Mermet-Meillon F; Apfel V; Barys L; Holzer L; Bachmann Salvy M; Lopes R; Amorim Monteiro Barbosa I; Delmas C; Hinniger A; Chau S; Kaufmann M; Haenni S; Berneiser K; Wahle M; Moravec I; Vissières A; Poetsch T; Ahrné E; Carte N; Voshol J; Bechter E; Hamon J; Meyerhofer M; Erdmann D; Fischer M; Stachyra T; Freuler F; Gutmann S; Fernández C; Schmelzle T; Naumann U; Roma G; Lawrenson K; Nieto-Oberhuber C; Cobos-Correa A; Ferretti S; Schübeler D; Galli GG
Nat Commun; 2021 Apr; 12(1):2442. PubMed ID: 33903593
[TBL] [Abstract][Full Text] [Related]
7. EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells.
De Weer A; Van der Meulen J; Rondou P; Taghon T; Konrad TA; De Preter K; Mestdagh P; Van Maerken T; Van Roy N; Jeison M; Yaniv I; Cauwelier B; Noens L; Poirel HA; Vandenberghe P; Lambert F; De Paepe A; Sánchez MG; Odero M; Verhasselt B; Philippé J; Vandesompele J; Wieser R; Dastugue N; Van Vlierberghe P; Poppe B; Speleman F
Br J Haematol; 2011 Aug; 154(3):337-48. PubMed ID: 21569010
[TBL] [Abstract][Full Text] [Related]
8. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
9. Transcription factor NFIC functions as a tumor suppressor in lung squamous cell carcinoma progression by modulating lncRNA CASC2.
Zhang H; Luo Z; Tang J; Tian J; Xiao Y; Sun C; Wang T
Cell Cycle; 2022 Jan; 21(1):63-73. PubMed ID: 34985387
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analyses of a CD8
Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
[TBL] [Abstract][Full Text] [Related]
11. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma.
Lei K; Liang R; Tan B; Li L; Lyu Y; Wang K; Wang W; Wang K; Hu X; Wu D; Lin H; Wang M
Oxid Med Cell Longev; 2023; 2023():6811625. PubMed ID: 36703911
[TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of Prognostic Regulation Network Based on RNA-Binding Protein Genes in Lung Squamous Cell Carcinoma.
Zhao S; Liu Q; Li J; Hu C; Cao F; Ma W; Gao J
DNA Cell Biol; 2021 Dec; 40(12):1563-1583. PubMed ID: 34931870
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of Osteopontin and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) for potential immunotherapeutic significance of in lung squamous cell carcinoma.
Shan G; Meihe L; Minchao K; Rui Z; Xiaopeng W; Guangjian Z; Jin Z
Int Immunopharmacol; 2022 Jun; 107():108715. PubMed ID: 35334357
[TBL] [Abstract][Full Text] [Related]
14. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
[TBL] [Abstract][Full Text] [Related]
15. Characterization of platelet-related genes and constructing signature combined with immune-related genes for predicting outcomes and immunotherapy response in lung squamous cell carcinoma.
Zhao S; Gong H; Liang W
Aging (Albany NY); 2023 Jul; 15(14):6969-6992. PubMed ID: 37477536
[TBL] [Abstract][Full Text] [Related]
16. MiR-4652-5p Targets RND1 to Regulate Cell Adhesion and Promote Lung Squamous Cell Carcinoma Progression.
Zhou Y; Yan J; Chen H; Zhou W; Xiao G; Zou H; Yang J
Appl Biochem Biotechnol; 2022 Jul; 194(7):3031-3043. PubMed ID: 35334070
[TBL] [Abstract][Full Text] [Related]
17. Protocadherin alpha 3 inhibits lung squamous cell carcinoma metastasis and epithelial-mesenchymal transition.
Tao Y; Fei L; Chang L; Yongyu L; Jianhui J; Yanan L; Yi R
Genes Genomics; 2022 Feb; 44(2):211-218. PubMed ID: 34086268
[TBL] [Abstract][Full Text] [Related]
18. LncRNA HHIP-AS1 suppresses lung squamous cell carcinoma by stabilizing HHIP mRNA.
Hu Z; Liu Y; Tang J; Luo R; Qin J; Mo Z; Xie J; Jiang X; Wei S; Lin C
Life Sci; 2023 May; 321():121578. PubMed ID: 36958438
[TBL] [Abstract][Full Text] [Related]
19. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
